Do you want to read an article? Please log in or register.
Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative
Hepatology
Indications
Related content
Gastrointestinal Cancer
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Int J Cancer
Rimini M, Lamarca A, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Vogel A, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Peeters F, Braconi C, Pinato DJ, Tamburini E, Pircher C, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Landriscina M, Finkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Formica V, de Sousa Pinto CM, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Changhoon Y, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Yung-Yeh S, Chan SL, Bolnykh I, Lancianese A, Satake T, Bekaii-Saab T, Lavacchi D, Passeri L, Ferrara M, Kang M, Viola MG, Bozzarelli S, Persano M, Masi G, Balsano R, Niger M, Lonardi S, Salani F, Camera S, Ratti F, Fornaro L, Rimassa L, Casadei-Gardini A
doi: 10.1002/ijc.70641
Gastrointestinal Cancer
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)
Eur J Cancer
Weiss L, Stintzing S, Modest DP, Stahler A, von Weikersthal LF, Reinacher-Schick A, Decker T, Probst V, Heinrich K, Schwaner I, Kaiser F, Pihusch R, Fuchs M, Held S, Alig A, Gruenberger B, Prager GW, Tougeron D, Taieb J, Heinemann V
doi: 10.1016/j.ejca.2025.116105
Gastrointestinal Cancer
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis
Eur J Cancer
Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F
doi: 10.1016/j.ejca.2025.116092
Hepatology
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
Clin Gastroenterol Hepatol
Younossi ZM, Kalligeros M, Wong VW, Al-Naamani KM, Tacke F, Tsochatzis E, Crespo J, El-Kassas M, Bril F, Arrese M, Caussy C, Spearman CW, Gastaldelli A, Pessoa MG, Gadano A, Shubrook JH, Duseja A, Eguchi Y, Chan WK, Fan JG, Holleboom AG, Yu ML, Kim J, Kawaguchi T, Villela-Nogueira C, Oliveria CP, Pik-Shan Kong A, Lam B, Giles H, Betel M, Ong J, Burra P, Yilmaz Y, Pearlman B, Buti M, Papatheodoridis G, Abreu ES, Abdelmalek M, Alkhouri N, Nader F, Stepanova M, Racila A, Paik J, Wajcman DI, Grinshpan LS, Roberts SK, Alqahtani SA, Zelber-Sagi S, Castera L, Henry L
doi: 10.1016/j.cgh.2026.03.030
Gastrointestinal Cancer
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
Lancet
Sun HC, Zhu XD, Shen F, Song TQ, Bai XL, Zeng YY, Chen MS, Huang ZY, Cai JQ, Gao J, Kuang M, Li DY, Xing BC, Li XC, Wen TF, Peng T, Wang YD, Liu LX, Huang C, Shi YH, Huang XW, Wang K, Gao Q, Zhou J, Fan J
doi: 10.1016/S0140-6736(26)01252-3
Gastrointestinal Cancer
Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial
Lancet Oncol
Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, West N, Quirke P, Sun Myint A, Bach S, Parsons P, Dhadda AS, Brown N, Brown G, Harrison M, Maggs R, Begum R, Chang E, Hackshaw A, Lopes A, ARISTOTLE Trial Management Group and Investigators
doi: 10.1016/S1470-2045(26)00132-4
Gastrointestinal Cancer
A 7-cm inflection point: nonlinear association between maximum tumor diameter and capsular invasion risk after primary liver cancer resection
BMC Gastroenterol
Zhang Y, Zhang G, Wang X, Ma Y, Li G
doi: 10.1186/s12876-025-04560-0
Gallbladder and Biliary Diseases
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
J Hepatol
Xu Q, Zhou S, Zhang C, Zhou Y, He Y, Jiang Y, Li J, Yi T, Luo C, Zhang L, Wu J, Zhang Y, Wu M, Wei Q, Li Q, Liu B, Chen X, Yao Y, Yu C, Li J, Ren Y, Zhuo W, Yuan L, Li W, Wang ZM, Li B, Xia M, Xie Y, Wu K, Ying J
doi: 10.1016/j.jhep.2026.06.033
Hepatitis
Early treatment initiation optimizes virologic and liver outcomes in pediatric patients with chronic hepatitis B aged 0-18 years
Clin Gastroenterol Hepatol
Chen L, Jiang L, Zhao B, Jiang Y, Liu S, Li M, Li Y, Jiang Y, Li M, Wei H, Bao C, Niu J, Zhao J
doi: 10.1016/j.cgh.2026.01.026